CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Porters five force analysis
3.4.Top player positioning, 2019
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Surge in geriatric population worldwide
3.5.1.2.Increase in healthcare expenditure worldwide coupled with surge in awareness towards treatment of high blood pressure
3.5.1.3.Rise in prevalence of hypertension across the globe

3.5.2.Restraint

3.5.2.1.Drug shortages of telmisartan tablets

3.5.3.Opportunities

3.5.3.1.High growth potential in developing economies

3.5.4.Impact analysis

3.6.Covid-19 Impact analysis on telmisartan market

CHAPTER 4:TELMISARTAN MARKET, BY INDICATION

4.1.Overview

4.1.1.Market size and forecast

4.2.Hypertension

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Cardiovascular risk reduction

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

CHAPTER 5:TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospital pharmacies

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Drug stores and retail pharmacies

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Online pharmacies

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:TELMISARTAN MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by country

6.2.2.1.U.S.

6.2.2.1.1.U.S. telmisartan market, by indication
6.2.2.1.2.U.S. telmisartan market, by distribution channel

6.2.2.2.Canada

6.2.2.2.1.Canada telmisartan market, by indication
6.2.2.2.2.Canada telmisartan market, by distribution channel

6.2.2.3.Mexico

6.2.2.3.1.Mexico telmisartan market, by indication
6.2.2.3.2.Mexico telmisartan market, by distribution channel
6.2.3.North America market size and forecast, by indication
6.2.4.North America market size and forecast, by distribution channel

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country

6.3.2.1.Germany

6.3.2.1.1.Germany telmisartan market, by indication
6.3.2.1.2.Germany telmisartan market, by distribution channel

6.3.2.2.France

6.3.2.2.1.France telmisartan market, by indication
6.3.2.2.2.France telmisartan market, by distribution channel

6.3.2.3.UK

6.3.2.3.1.UK telmisartan market, by indication
6.3.2.3.2.UK telmisartan market, by distribution channel

6.3.2.4.Italy

6.3.2.4.1.Italy telmisartan market, by indication
6.3.2.4.2.Italy telmisartan market, by distribution channel

6.3.2.5.Spain

6.3.2.5.1.Spain telmisartan market, by indication
6.3.2.5.2.Spain telmisartan market, by distribution channel

6.3.2.6.Rest of Europe

6.3.2.6.1.Rest of Europe telmisartan market, by indication
6.3.2.6.2.Rest of Europe telmisartan market, by distribution channel

6.3.3.Europe market size and forecast, by indication
6.3.4.Europe market size and forecast, by distribution channel

6.4.Asia-Pacific

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by country

6.4.2.1.Japan

6.4.2.1.1.Japan telmisartan market, by indication
6.4.2.1.2.Japan telmisartan market, by distribution channel

6.4.2.2.China

6.4.2.2.1.China telmisartan market, by indication
6.4.2.2.2.China telmisartan market, by distribution channel

6.4.2.3.Australia

6.4.2.3.1.Australia telmisartan market, by indication
6.4.2.3.2.Australia telmisartan market, by distribution channel

6.4.2.4.India

6.4.2.4.1.India telmisartan market, by indication
6.4.2.4.2.India telmisartan market, by distribution channel

6.4.2.5.South Korea

6.4.2.5.1.South Korea telmisartan market, by indication
6.4.2.5.2.South Korea telmisartan market, by distribution channel

6.4.2.6.Rest of Asia-Pacific

6.4.2.6.1.Rest of Asia-Pacific telmisartan market, by indication
6.4.2.6.2.Rest of Asia-Pacific telmisartan market, by distribution channel

6.4.3.Asia-Pacific market size and forecast, by indication
6.4.4.Asia-Pacific market size and forecast, by distribution channel

6.5.LAMEA

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by country

6.5.2.1.Brazil

6.5.2.1.1.Brazil telmisartan market, by indication
6.5.2.1.2.Brazil telmisartan market, by distribution channel

6.5.2.2.Saudi Arabia

6.5.2.2.1.Saudi Arabia telmisartan market, by indication
6.5.2.2.2.Saudi Arabia telmisartan market, by distribution channel

6.5.2.3.South Africa

6.5.2.3.1.South Africa telmisartan market, by indication
6.5.2.3.2.South Africa telmisartan market, by distribution channel

6.5.2.4.Rest of LAMEA

6.5.2.4.1.Rest of LAMEA telmisartan market, by indication
6.5.2.4.2.Rest of LAMEA telmisartan market, by distribution channel

6.5.3.LAMEA market size and forecast, by indication
6.5.4.LAMEA market size and forecast, by distribution channel

CHAPTER 7:COMPANY PROFILES

7.1.ABBOTT LABORATORIES

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.AUROBINDO PHARMA

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance.

7.3.BOEHRINGER INGELHEIM INTERNATIONAL GMBH

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance

7.4.CIPLA INC.

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance

7.5.GLAXOSMITHKLINE PLC (GSK)

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance.

7.6.MYLAN N.V.

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance

7.7.SANOFI

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance

7.8.SUN PHARMACEUTICAL INDUSTRIES LIMITED

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance

7.9.TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance

7.10.ZYDUS CADILA

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance.
7.10.6.Key strategic moves and developments